Drugs / ABY-029
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT03282461 | Jan 2018 → Dec 2020 | head and neck cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03154411 | Aug 2017 → Dec 2020 | soft tissue sarcoma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT02901925 | Feb 2017 → Jun 2021 | glioma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07279116 | Jun 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | Dartmouth-Hitchcock Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07063693 | Feb 2026 → Jul 2028 expected | brain neoplasm | Dartmouth-Hitchcock Medical Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABY-029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07063693 ↗ |
| Known as | ABY-029 trifluoroacetate salt | “ABY-029 trifluoroacetate salt” NCT03282461 ↗ |
| Modality | Peptide | “IRDye® 800CW Maleimide labeled Affibody peptide” NCT02901925 ↗ |
| Route | Intravenous | “administered via single intravenous injection” NCT02901925 ↗ |
| Target | EGFR | “binding with EGFR positive tumor tissue” NCT02901925 ↗ |